Patents Assigned to Palatin Technologies, Inc.
  • Patent number: 10711039
    Abstract: Melanocortin receptor-specific peptides with a C-terminal naphthylalanine of the formula: where R4, R7, R9, R11, R18, R20, R21a, R21b, R21c and R22 are as defined in the claims, compositions and formulations including the peptides of the foregoing formula or salts thereof, and methods of preventing, ameliorating or treating melanocortin receptor-mediated or responsive diseases, indications, conditions and syndromes.
    Type: Grant
    Filed: January 17, 2018
    Date of Patent: July 14, 2020
    Assignee: Palatin Technologies, Inc.
    Inventors: Wei Yang, Yi-Qun Shi
  • Patent number: 10660939
    Abstract: The invention relates to methods, uses, compositions and formulations including a melanocortin receptor-4 agonist and a glucagon-like peptide-1 receptor agonist for treatment of obesity, diabetes, metabolic syndrome and related indications, diseases or disorders.
    Type: Grant
    Filed: October 3, 2017
    Date of Patent: May 26, 2020
    Assignee: Palatin Technologies, Inc.
    Inventors: Carl Spana, John H. Dodd, Marie Makhlina
  • Patent number: 10632171
    Abstract: Melanocortin receptor-specific cyclic peptides of the formula where R1, R3, R4, R9 and R10 are as defined in the specification, compositions and formulations including the peptides of the foregoing formula, and methods of preventing, ameliorating or treating melanocortin receptor-mediated diseases, indications, conditions and syndromes.
    Type: Grant
    Filed: January 11, 2019
    Date of Patent: April 28, 2020
    Assignee: Palatin Technologies, Inc.
    Inventors: Yi-qun Shi, Shubh D Sharma, John H Dodd, Wei Yang, Xin Chen
  • Patent number: 10286034
    Abstract: Use of a subcutaneously administered dose of between about 1.25 mg and 1.75 mg of bremelanotide or a pharmaceutically acceptable salt of bremelanotide for the treatment of female sexual dysfunction in women while reducing or minimizing undesirable side effects.
    Type: Grant
    Filed: July 6, 2017
    Date of Patent: May 14, 2019
    Assignee: Palatin Technologies, Inc.
    Inventors: Carl Spana, Robert Jordan, Jeffrey D. Edelson
  • Patent number: 10179804
    Abstract: Melanocortin receptor-specific cyclic peptides of the formula where R1, R2, R3, R4, R5, R6, R7, R8, R9, R10 and z are as defined in the specification, compositions and formulations including the peptides of the foregoing formula, and methods of preventing, ameliorating or treating melanocortin receptor-mediated diseases, indications, conditions and syndromes.
    Type: Grant
    Filed: July 20, 2016
    Date of Patent: January 15, 2019
    Assignee: Palatin Technologies, Inc.
    Inventors: Yi-qun Shi, Shubh D. Sharma, John H. Dodd, Wei Yang
  • Patent number: 10106578
    Abstract: Melanocortin receptor-specific linear peptides of the formula Z-Xaa1-Xaa2-Xaa3-Xaa4-Xaa5-Xaa6-Y??(VI) or a pharmaceutically acceptable salt thereof, where Z, Y, Xaa1, Xaa2, Xaa3, Xaa4, Xaa5, and Xaa6 are as defined in the specification, compositions and formulations including peptides of the foregoing formula or salts thereof, and pharmaceutical compositions for preventing, ameliorating or treating melanocortin-1 receptor-mediated or responsive diseases, indications, conditions and syndromes.
    Type: Grant
    Filed: February 2, 2017
    Date of Patent: October 23, 2018
    Assignee: Palatin Technologies, Inc.
    Inventors: Wei Yang, Yi-Qun Shi
  • Patent number: 10017539
    Abstract: Melanocortin receptor-specific cyclic hexapeptides of the formula where R1, R2, R3, R4, R5, R6, R7, R8 and R9 are as defined in the claims, compositions and formulations including the hexapeptides of the foregoing formula or salts thereof, and methods of preventing, ameliorating or treating melanocortin-1 receptor-mediated or responsive diseases, indications, conditions and syndromes.
    Type: Grant
    Filed: September 19, 2016
    Date of Patent: July 10, 2018
    Assignee: Palatin Technologies, Inc.
    Inventors: Wei Yang, Yi-Qun Shi
  • Patent number: 9700592
    Abstract: Use of a subcutaneously administered dose of between about 1.0 mg and 1.75 mg of bremelanotide or a pharmaceutically acceptable salt of bremelanotide for the treatment of female sexual dysfunction in women while reducing or minimizing undesirable side effects.
    Type: Grant
    Filed: May 5, 2015
    Date of Patent: July 11, 2017
    Assignee: Palatin Technologies, Inc.
    Inventors: Carl Spana, Robert Jordan, Jeffrey D. Edelson
  • Patent number: 9580466
    Abstract: Melanocortin receptor-specific linear peptides of the formula where R1, R2, R3, R4, R5, R6, R7, R8, R9 and R10 are as defined in the specification, compositions and formulations including peptides of the foregoing formula or salts thereof, and pharmaceutical compositions for preventing, ameliorating or treating melanocortin-1 receptor-mediated or responsive diseases, indications, conditions and syndromes.
    Type: Grant
    Filed: December 30, 2014
    Date of Patent: February 28, 2017
    Assignee: Palatin Technologies, Inc.
    Inventors: Wei Yang, Yi-Qun Shi
  • Patent number: 9458201
    Abstract: Melanocortin receptor-specific cyclic heptapeptides of the formula Z-Xaa1-Xaa2-Xaa3-Xaa4-Xaa5-Xaa6-Xaa7-Y??(II) or a pharmaceutically acceptable salt thereof, where Z, Xaa1, Xaa2, Xaa3, Xaa4, Xaa5, Xaa6, Xaa7 and Y are as defined in the specification, compositions and formulations including the peptides of the foregoing formula, and methods of preventing, ameliorating or treating melanocortin receptor-mediated diseases, indications, conditions and syndromes.
    Type: Grant
    Filed: July 11, 2014
    Date of Patent: October 4, 2016
    Assignee: Palatin Technologies, Inc.
    Inventors: Yi-qun Shi, Shubh D. Sharma, John H. Dodd, Wei Yang
  • Patent number: 9447148
    Abstract: Melanocortin receptor-specific cyclic peptides of the formula where R1, R2, R3, R4, R5, R6, R7, R8 and R9 are as defined in the specification, compositions and formulations including the peptides of the foregoing formula or salts thereof, and methods of preventing, ameliorating or treating melanocortin-1 receptor-mediated or responsive diseases, indications, conditions and syndromes.
    Type: Grant
    Filed: October 15, 2014
    Date of Patent: September 20, 2016
    Assignee: Palatin Technologies, Inc.
    Inventors: Wei Yang, Yi-Qun Shi
  • Patent number: 9352013
    Abstract: Use of a subcutaneously administered dose of between about 1.0 mg and 1.75 mg of bremelanotide or a pharmaceutically acceptable salt of bremelanotide for the treatment of female sexual dysfunction in women while reducing or minimizing undesirable side effects.
    Type: Grant
    Filed: June 24, 2014
    Date of Patent: May 31, 2016
    Assignee: Palatin Technologies, Inc.
    Inventors: Carl Spana, Robert Jordan, Jeffrey D. Edelson
  • Patent number: 9273098
    Abstract: Lactam-bridged melanocortin receptor-specific cyclic peptides of the formula where R1, R2, R3, R4, R5, R6, R7, R8 and R9 are as defined in the specification, compositions and formulations including the peptides of the foregoing formula, and methods of preventing, ameliorating or treating melanocortin receptor-mediated diseases, indications, conditions and syndromes, including obesity, modulation of feeding behavior, related metabolic syndrome, sexual dysfunction, male erectile dysfunction and female sexual dysfunction.
    Type: Grant
    Filed: December 6, 2011
    Date of Patent: March 1, 2016
    Assignee: Palatin Technologies, Inc.
    Inventors: Xin Chen, Wei Yang
  • Patent number: 8933194
    Abstract: Melanocortin receptor-specific linear peptides of the formula where R1, R2, R3, R4, R5, R6, R7, R8, R9 and R10 are as defined in the specification, compositions and formulations including peptides of the foregoing formula or salts thereof, and pharmaceutical compositions for preventing, ameliorating or treating melanocortin-1 receptor-mediated or responsive diseases, indications, conditions and syndromes.
    Type: Grant
    Filed: May 16, 2012
    Date of Patent: January 13, 2015
    Assignee: Palatin Technologies, Inc.
    Inventors: Wei Yang, Yi-Qun Shi
  • Patent number: 8877890
    Abstract: Melanocortin receptor-specific cyclic peptides of the formula where R1, R2, R3, R4, R5, R6, R7, R8 and R9 are as defined in the specification, compositions and formulations including the peptides of the foregoing formula or salts thereof, and methods of preventing, ameliorating or treating melanocortin-1 receptor-mediated or responsive diseases, indications, conditions and syndromes.
    Type: Grant
    Filed: June 5, 2013
    Date of Patent: November 4, 2014
    Assignee: Palatin Technologies, Inc.
    Inventors: Wei Yang, Yi-Qun Shi
  • Patent number: 8846601
    Abstract: Melanocortin receptor-specific cyclic peptides of the formula where R1, R2, R3, R4, R5, R6, R7, R8, R9, R10 and z are as defined in the specification, compositions and formulations including the peptides of the foregoing formula, and methods of preventing, ameliorating or treating melanocortin receptor-mediated diseases, indications, conditions and syndromes.
    Type: Grant
    Filed: December 6, 2011
    Date of Patent: September 30, 2014
    Assignee: Palatin Technologies, Inc.
    Inventors: Yi-qun Shi, Shubh D. Sharma, John H. Dodd, Wei Yang, Xin Chen
  • Patent number: 8828926
    Abstract: Use of constructs which bind to one or more natriuretic peptide receptors and include a plurality of amino acid residues and at least one amino acid surrogate of formula I: where R, R?, Q, Y, W, Z, J, x and n are as defined in the specification, and optionally at least one prosthetic group, for the prophylaxis or treatment of airway diseases, including but not limited to inflammation-related airway diseases, acute asthma or chronic obstructive pulmonary disease, methods of prophylaxis and treatment of airway diseases and pharmaceutical compositions and formulations for the prophylaxis or treatment of airway diseases.
    Type: Grant
    Filed: October 17, 2012
    Date of Patent: September 9, 2014
    Assignee: Palatin Technologies, Inc.
    Inventors: Margarita Bastos, Jennifer Lata, Jeffrey D. Edelson
  • Patent number: 8729224
    Abstract: Methods for use of a melanocortin receptor agonist cyclic peptide of the formula where R, x and y are as defined in the specification, and compositions and formulations including the peptide of the foregoing formula, for preventing, ameliorating or treating female sexual dysfunction.
    Type: Grant
    Filed: June 5, 2013
    Date of Patent: May 20, 2014
    Assignee: Palatin Technologies, Inc.
    Inventors: Yi-Qun Shi, Shubh D. Sharma, Wei Yang, Xin Chen
  • Patent number: 8580746
    Abstract: Cyclic constructs which bind to a natriuretic peptide receptor and include a plurality of amino acid residues, at least one amino acid surrogate of formula I: where R, R?, Q, Y, W, Z, J, x and n are as defined in the specification, and a cyclic linkage including one or two amide bonds, pharmaceutical compositions including such cyclic constructs, and methods of treating congestive heart failure or other conditions, syndromes or diseases for which induction of anti-hypertensive, cardiovascular, renal or endocrine effects are desired.
    Type: Grant
    Filed: October 2, 2009
    Date of Patent: November 12, 2013
    Assignee: Palatin Technologies, Inc.
    Inventors: Shubh D. Sharma, Margarita Bastos, Wei Yang
  • Patent number: 8580747
    Abstract: Cyclic constructs with an N-terminus and a C-terminus which bind to a natriuretic peptide receptor and include a plurality of amino acid residues, at least one amino acid surrogate of formula I: where R, R?, Q, Y, W, Z, J, x and n are as defined in the specification, and optionally at least one prosthetic group, pharmaceutical compositions including such cyclic constructs, and methods of treating congestive heart failure or other conditions, syndromes or diseases for which induction of anti-hypertensive, cardiovascular, renal or endocrine effects are desired.
    Type: Grant
    Filed: November 19, 2009
    Date of Patent: November 12, 2013
    Assignee: Palatin Technologies, Inc.
    Inventors: Shubh D. Sharma, Margarita Bastos, Wei Yang, Hui-Zhi Cai